Horizon Therapeutics Announces Significant Expansion and Relocation of U.S. Operations
Horizon Therapeutics Announces Significant Expansion and Relocation of U.S. Operations
“Lake County has a rich life sciences ecosystem and we are looking forward to continuing to contribute to and lead the growth of that ecosystem,” said
The
“Illinois’ biopharmaceutical industry has a deep talent pool, and a bright future, and we’ll continue to invest in making sure that this industry can continue to be a crucial job creation engine, as well as developing treatments and potential cures for patients locally and globally,” said Governor JB Pritzker. “I am pleased to see the continued growth of
“The Governor recognizes the importance of a health life sciences sector, which is why it’s a critical part of the five-year economic development plan,” said Acting Director of the
“I am thrilled to welcome Horizon back to Deerfield,” said
Horizon is being represented in the transaction by
About Horizon
Horizon is focused on researching, developing and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases. Our pipeline is purposeful: we apply scientific expertise and courage to bring clinically meaningful therapies to patients. We believe science and compassion must work together to transform lives. For more information on how we go to incredible lengths to impact lives, please visit www.horizontherapeutics.com, follow us @HorizonNews on Twitter, like us on
Forward Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements related to the timing of closing the real estate transaction and Horizon’s relocation of its U.S. operations, the potential benefits of the new U.S. operations, potential future growth of Horizon’s business and employee base, and other statements that are not historical facts. These forward-looking statements are based on Horizon’s current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to the satisfaction of closing conditions related to the real estate transaction, Horizon’s ability to grow sales and revenues from existing medicines, Horizon’s ability to complete the planned relocation of its U.S. operations on anticipated timelines, whether the new facilities will be adequate for Horizon’s future needs, and those risks detailed from time-to-time under the caption "Risk Factors" and elsewhere in Horizon's filings and reports with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20200128005606/en/
Source:
U.S. Media Contact:
Geoff Curtis
Executive Vice President, Corporate Affairs and Chief Communications Officer
media@horizontherapeutics.com
Investor Contacts:
Tina Ventura
Senior Vice President, Investor Relations
Investor-relations@horizontherapeutics.com
Ruth Venning
Executive Director, Investor Relations
Investor-relations@horizontherapeutics.com
Ireland Media Contact:
Gordon MRM
Ray Gordon
ray@gordonmrm.ie